More MDUFMA Guidance: FDA Clarifies Performance Goal Review Clock Rules
This article was originally published in The Gray Sheet
Executive Summary
FDA will grant PMA sponsors an extension of up to 180 days to respond to major deficiencies, the agency notes in a guidance outlining various device review actions and their impact on FDA fulfillment of user fee performance goals